

**NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**MINUTES**  
**DECEMBER 16, 2014**

**CALL TO ORDER / ANNOUNCEMENTS**

The NCI at Frederick Institutional Biosafety Committee was convened at 12:05 pm in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 8)

Katalin Baranji (*regrets*)  
 Michael Baseler  
 Theresa Bell  
 Rev. David Betzner  
 Stephen Creekmore (*regrets*)  
 Bruce Crise  
 Eric Freed  
 Melinda Hollingshead

Stephen Hughes  
 Sarah Hooper  
 Serguei Kozlov  
 Dan McVicar  
 Raja Sriperumbudur (*regrets*)  
 Lucien Winegar  
 Sharon Altmann

Non-Voting

Walter Hubert  
 Karen Barber  
 Matthew Nawn

**APPROVAL OF MINUTES FROM THE NOVEMBER 18 MEETING**

The minutes from the November 18, 2014 meeting were approved. A motion and second were made.  
(For: 12; Against: 0; Abstain: 0)

**ACCIDENT REVIEWS :**

**REVIEW OF PROTOCOLS**

***NEW REGISTRATIONS***

- ❖ Lawrence Samelson – 14-45 – Breeding only protocol – **Notification only** – Generate mice to study the effects of cell signaling downstream of the gene LAT on immune regulation. (Hollingshead)
- ❖ Jeffrey Lifson – 14-44 (11-09) – Pathogenesis and immunological control of human and non-human primate retroviruses – Retroviruses, including mainly HIV-1, SIV, HIV-2, chimeric SIV/HIV and XMRV will be studied, examining properties and requirements of viral replication and immune responses necessary for control of viral infections. Some of this work will involve the use of full-length proviral plasmids that will be transfected into cell cultures to generate viruses for study. The viruses generated will be examined for replicative properties in cell culture using established cell-lines, or primary cells isolated from humans or macaques. A motion to approve was made by Mike Baseler and seconded by Steve Hughes. (For: 12; Against: 0; Abstain: 0)

**NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**MINUTES**  
**DECEMBER 16, 2014**

❖ **RENEWAL REGISTRATIONS**

**OUTSTANDING ITEMS**

- ❖ Matthew Holderfield – 14-40 – RAS screening assay development and biological characterization – This lab is interested in KRAS driven cancers and are currently developing cellular and biochemical assays that will be used for high throughput screening to identify compounds that prevent or disrupt protein-protein interactions involving KRAS. The focus is to understand the nature of KRAS-CRAF and KRAS-Calmodulin binding and mechanisms of KRAS dependent proliferation. The committee needs more information and clarifications. A motion to approve was made by Bruce Crise and seconded by Sharon Altmann. There is a stipulation that the post exposure prophylactics will be in place before the work is to begin. (For: 12; Against: 0; Abstain: 0)
- ❖ Peter Gorelick – 14-26 (08-27). Serological diagnostic testing of non-human primates for the presence of potentially adventitious viruses - Diagnostic serological testing for routine health monitoring of NHPs. (Bell) Deferred to full committee in August. Awaiting additional documentation.
- ❖ Stephen Lockett – 14-22 (08-46) – Ras project 3 and CCR support. Discovery methods to directly target oncogenic Ras protein, and live and fixed cell fluorescence labeling in support of CCR research. (Zudaire/Hughes/Altmann) Deferred to full committee in August. Awaiting additional documentation. **ON HOLD. WAITING ON CHANGES IN THE DEPARTMENT BEFORE SUBMITTING. As of October 14, 2014, no updates have been made.**
- ❖ Dimitar Dimitrov 13-38 (04-04, 08-20): Developing anti-viral vaccines and human antibodies against infectious diseases and cancer antigens by using recombinant membrane proteins of HIV, Nipah, Hendra, Dengue viruses and cancer antigens. Committee requested additional clarifications and a Vaccinia-specific SOP as well as a lab visit. Post-meeting, Theresa Bell learned that the lab was relocating and suggested that the space that will be used for the Vaccinia work should not be evaluated until the move has been completed. No Vaccinia work is being performed at this time. **Continue deferral until lab move and observation is completed.** For: 8; Against: 0; Abstain: 0

**AMENDMENTS**

Twenty five amendments were processed and approved between November and December IBC meetings.

**OTHER BUSINESS**

**ADJOURNMENT**

The meeting adjourned at 1:10 pm.

**Next meetings:**

**January 20, 2014**

**February 17, 2015**